MenaQ7^®, now recognized by JAMA Cardiology,
#5 cardiovascular journal worldwide

Download our exclusive infographic to explore VitaK-CAC, the first clinical trial showing the effect of stand-alone Vitamin K2 MK-7 supplementation on the progression of Coronary Artery Calcification (CAC).

Coronary Artery Calcification (CAC) develops early in the pathogenesis of atherosclerosis, driven by an imbalance between mechanisms that promote and inhibit calcium deposition in the vascular wall. As the progression of this process reflects advanced vascular aging and serves as a strong predictor of cardiovascular disease, finding effective ways to manage CAC progression is a critical goal for the health supplement industry.

The 2-year VitaK-CAC trial, which used MenaQ7® as the source material, demonstrated:

• 29% lower progression in new coronary artery calcification
• 42% less progression in calcium mass
•  1^st trial with significant results not seen in previous trials with such low-dose vitamin K or drugs

 Discover VitaK-CAC study.